Die Behandlung des M. Menière mit Betahistin: Kritische Anmerkungen zur BEMED-Studie.

Die Behandlung des M. Menière mit Betahistin: Kritische Anmerkungen zur BEMED-Studie.

Laryngorhinootologie. 2017 Aug;96(8):519-521

Authors: Ernst A, Schlattmann P, Waldfahrer F, Westhofen M

Abstract
The BEMED study (BMJ 2016; 352: DOI 10.1136) was designed as multi-centric, double-blind, plaebo-controlled study in patients with Menière's disease. It should compare a low-level (2 × 24 mg/d) vs. high-level (3 × 48 mg/d) betahstine intake vs. placebo. The primary endpoint was the "number of vertigo attacks lasting longer than 20 min as documented in a patient's diary". The main finding of the study was that betahistine did not significantly better reduced the number of vertigo attacks than placebo. Therefore, the BEMED study should be critically discussed in the present paper.

PMID: 28850992 [PubMed - in process]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2xMsnXL